Post Archive
More Studies on Metformin and Survival
In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.
Education Department September 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Sponsor a Student
SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.
Introducing the SRF-University of Toledo PhD Program
We are thrilled to announce the launch of a joint PhD program between SENS Research Foundation and the University of Toledo Biological Sciences Department. This program offers a unique opportunity for aspiring researchers to pursue their doctoral degree in the cutting-edge field of anti-aging research, with a damage-repair approach.
Education Department August 2023 Updates
Read more about SRF Education programs highlights and upcoming events.
Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials
TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.
The Grand Opening of Our New Facilities
June 23, 2023 – SRF had the Grand Opening of our expanded Research Center in Mountain View, CA. In attendance were local and state dignitaries, members of the SRF Board, SRF senior staff and scientific leads, SRF staff and Education program participants, and a number of distinguished and welcome guests.
Education Department July 2023 Updates
The 2023 application season is coming to a close with a very competitive applicant pool. Read more about highlights and upcoming events.
From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done
Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.
Lights, Camera, Action on AI-Powered Drug Discovery
Docuthon is the world’s first documentary-creating competition on AI-powered drug discovery, providing an opportunity for every talented filmmaker to get involved in a cutting-edge industry, share a terrific science story, and inspire the next generation of scientists in longevity.
SENSible Question: Billionaires Redux
A supporter raises a new angle on an old concern: might fabulously wealthy people hoard longevity therapeutics for themselves? The context for the question and the motivation behind it are different, but the answer is still “no.” Rejuvenation biotechnology will be widely available to aging people, and SENS Research Foundation will work at the front end and the back end to ensure that access to longevity therapeutics expands as quickly and as widely as possible.
Education Department May 2023 Updates
The 2023 application season is coming to a close with a very competitive applicant pool. Read more about highlights and upcoming events.
An Oil Change is Not a Gasket Change: Insights from the Interaction of “Old Blood” and Senolytic Therapy
When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.
Kneecapped by Aging: New and Scrutinized Science Suggests Why the UNITY Osteoarthritis Trial Failed
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?
A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.
Announcing the Biomarkers of Aging Consortium
A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…
Action at the Governmental Level for Longevity
As partners of the Alliance for Longevity Initiatives (A4LI), SRF is excited to announce the formation of the Longevity Science Caucus to promote initiatives aimed at increasing the healthy average lifespan of all Americans. Read more…
The Iron Fist Unleashed!
One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.
